Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age23-64
SponsorRigshospitalet, Denmark

About this trial

This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion.

The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning.

Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion.

The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 23-50 years

BMI 20.0-26.9 kg/m²

HbA1c < 42 mmol/mol

Able to provide informed consent

Disqualifiers

Anaemia (haemoglobin below normal range)

ALT > 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder

Kidney disease (creatinine above normal range)

Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)

Trial design

Design model

Crossover

Treatments tested in this trial

  • GIP

    Drug

    Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of 6 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology

  • GLP-1

    Drug

    Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology.

  • Saline (0.9% Sodium Chloride)

    Other intervention

    Intravenous infusion of isotonic saline administered as placebo. In sub-study 1, saline serves as a control condition; in sub-study 2, saline is infused for 15 minutes prior to hormone infusion.

Treatment groups

36 Participants
are divided into 3 treatment groups
Group A: GIP infusionExperimental treatment 1 intervention
Group B: GLP-1 infusionExperimental treatment 1 intervention
Group C: Saline PlaceboExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Metabolic Rate of FDG

MRFDG quantified using dynamic total-body 18F-FDG PET with 3-compartment kinetic modelling during infusion of GIP, GLP-1, or placebo.

Time frame
75 minuts

Secondary outcomes

1

Perfusion of skeletal muscle

Time frame
75 min

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.